BRIACELL THERAPEUTICS CORP. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
BRIACELL THERAPEUTICS CORP. (BCTX) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$7.24 million for the 3-month period ending 2026-04-30, per its 10-Q filed 2026-06-09.
Financial Statements › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2026-06-09
- BRIACELL THERAPEUTICS CORP. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-04-30 was -$7.24M.
- BRIACELL THERAPEUTICS CORP. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-01-31 was -$7.30M.
- BRIACELL THERAPEUTICS CORP. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-10-31 was -$8.28M.
- BRIACELL THERAPEUTICS CORP. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-07-31 was -$8.16M.
- BRIACELL THERAPEUTICS CORP. net income (loss), including portion attributable to noncontrolling interest for fiscal 2025 was -$26.56M.
- BRIACELL THERAPEUTICS CORP. net income (loss), including portion attributable to noncontrolling interest for fiscal 2024 was -$4.93M.
- BRIACELL THERAPEUTICS CORP. net income (loss), including portion attributable to noncontrolling interest for fiscal 2023 was -$20.30M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-04-30 | -$7.24M 10-Q · filed 2026-06-09 | -$14.53M derived: sum of 2 quarters · filed 2026-06-09 | -$22.81M 10-Q · filed 2026-06-09 | -$30.98M derived: sum of 4 quarters · filed 2026-06-09 |
| 2026-01-31 | -$7.30M 10-Q · filed 2026-03-10 | -$15.58M 10-Q · filed 2026-03-10 | -$23.74M derived: sum of 3 quarters · filed 2026-03-10 | -$29.96M derived: sum of 4 quarters · filed 2026-06-09 |
| 2025-10-31 | -$8.28M 10-Q · filed 2025-12-11 | -$16.44M derived: sum of 2 quarters · filed 2025-12-11 | -$22.67M derived: sum of 3 quarters · filed 2026-06-09 | -$29.01M derived: sum of 4 quarters · filed 2026-06-09 |
| 2025-07-31 | -$8.16M derived: 10-K 12 month − 10-Q 9 month · filed 2025-10-16 | -$14.39M derived: sum of 2 quarters · filed 2026-06-09 | -$20.73M derived: sum of 3 quarters · filed 2026-06-09 | -$26.56M 10-K · filed 2025-10-16 |
| 2025-04-30 | -$6.22M 10-Q · filed 2026-06-09 | -$12.56M derived: sum of 2 quarters · filed 2026-06-09 | -$18.39M 10-Q · filed 2026-06-09 | -$19.64M derived: sum of 4 quarters · filed 2026-06-09 |
| 2025-01-31 | -$6.34M 10-Q · filed 2026-03-10 | -$12.17M 10-Q · filed 2026-03-10 | -$13.42M derived: sum of 3 quarters · filed 2026-03-10 | -$11.72M derived: sum of 4 quarters · filed 2026-03-10 |
| 2024-10-31 | -$5.83M 10-Q · filed 2025-12-11 | -$7.08M derived: sum of 2 quarters · filed 2025-12-11 | -$5.39M derived: sum of 3 quarters · filed 2025-12-11 | -$16.72M derived: sum of 4 quarters · filed 2025-12-11 |
| 2024-07-31 | -$1.25M derived: 10-K 12 month − 10-Q 9 month · filed 2025-10-16 | $443.49K derived: sum of 2 quarters · filed 2025-10-16 | -$10.89M derived: sum of 3 quarters · filed 2025-10-16 | -$4.93M 10-K · filed 2025-10-16 |
| 2024-04-30 | $1.69M 10-Q · filed 2025-06-16 | -$9.64M derived: sum of 2 quarters · filed 2025-06-16 | -$3.68M 10-Q · filed 2025-06-16 | -$6.10M derived: sum of 4 quarters · filed 2025-06-16 |
| 2024-01-31 | -$11.33M 10-Q · filed 2025-03-12 | -$5.38M 10-Q · filed 2025-03-12 | -$7.79M derived: sum of 3 quarters · filed 2025-03-12 | -$12.69M derived: sum of 4 quarters · filed 2025-03-12 |
| 2023-10-31 | $5.96M 10-Q · filed 2024-12-16 | $3.54M derived: sum of 2 quarters · filed 2024-12-16 | -$1.36M derived: sum of 3 quarters · filed 2024-12-16 | -$13.24M derived: sum of 4 quarters · filed 2024-12-16 |
| 2023-07-31 | -$2.42M derived: 10-K 12 month − 10-Q 9 month · filed 2024-10-29 | -$7.31M derived: sum of 2 quarters · filed 2024-10-29 | -$19.20M derived: sum of 3 quarters · filed 2024-10-29 | -$20.30M 10-K · filed 2024-10-29 |
| 2023-04-30 | -$4.90M 10-Q · filed 2024-06-14 | -$16.78M derived: sum of 2 quarters · filed 2024-06-14 | -$17.88M 10-Q · filed 2024-06-14 | |
| 2023-01-31 | -$11.88M 10-Q · filed 2024-03-18 | -$12.99M 10-Q · filed 2024-03-18 | ||
| 2022-10-31 | -$1.11M 10-Q · filed 2023-12-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |